March 21st 2025
Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States.
A look at the current landscape and how young companies can set the stage for product launch.
Sanofi Bolsters Immunology Pipeline with Acquisition of Dren Bio’s DR-0201 for Up to $1.9 Billion
March 20th 2025DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.
Practical Steps for Better Cross-Functional Collaboration
March 20th 2025Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, explores practical steps pharmaceutical executives can take to foster better collaboration within their organizations, as well as with external partners like providers and pharmacies.
Phase III Trials Show Povorcitinib Significantly Improves Hidradenitis Suppurativa Outcomes
March 19th 2025In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.
The 2025 Medication Access Report: Biggest Bottlenecks for Patients
March 19th 2025Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, highlights gaps in data sharing and cross-functional collaboration as major bottlenecks that are causing delays, rework, and increased patient burden.
Understanding the Real Needs of Families: Advancing Hearing Solutions for Children and Adults
March 17th 2025Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how the focus of technology development is shifting toward ensuring safety and continuous hearing for children.
Applying Porter’s Five Forces to Portfolio Management in Pharmaceutical R&D: A Strategic Roadmap
March 17th 2025The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage.